Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) has received $2m grant from Boehringer Ingelheim to study the drug candidate, Afatinib (BIBW 2992) in solid tumors.
Subscribe to our email newsletter
Afatinib is an oral, once-daily, tyrosine kinase inhibitor which is being investigated for various tumor types including non-small cell lung (NSCL), breast, head and neck, and colorectal cancers and glioblastoma.
Currently, the compound is in Phase III clinical development for NSCL and breast cancers.
NCCN ORP vice president Diane Paul said the grant will help scientists and clinicians find new directions to advance the field of oncology.
"Our collaboration will provide a forum for the open exchange of information to better define the clinical application for the use of Afatinib in a variety of cancer types," Paul added.